INU-101

potent and selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1)

Also Known As:

(1S,3R,4S,5S,7S)-4-(2-((2-fluorophenyl)sulfonamido)-2-methylpropanamido)adamantane-1-carboxamide

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Body Weight (Weight, Body) 09/15/2018 - "Furthermore, INU-101 treatment decreased the body weight and ameliorated an improved lipid profile in the diabetic mouse model. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/15/2018 - "These results suggest that the 11β-HSD1 inhibitor, INU-101 may serve as a novel drug candidate for the treatment of type 2 diabetes and metabolic syndrome."
3.	Insulin Resistance 09/15/2018 - "In KKAy mice, ob/ob mice and ZDF rats, the oral administration of INU-101 enhanced insulin sensitivity and lowered the fasting blood glucose level. "
4.	Type 2 Diabetes Mellitus (MODY) 09/15/2018 - "These results suggest that the 11β-HSD1 inhibitor, INU-101 may serve as a novel drug candidate for the treatment of type 2 diabetes and metabolic syndrome."

1.	Oral Administration